Subscribe

Shitanshu Uppal

GeDDiS Trial: Gemcitabine and docetaxel versus doxorubicin as first-line treatment sarcomas

Doxorubicin remains the standard first-line treatment for most patients with advanced soft-tissue sarcoma, as gemcitabine and docetaxel did not demonstrate superiority in survival outcomes

Trabectedin

LMS-04: Doxorubicin alone versus doxorubicin with trabectedin for metastatic or unresectable leiomyosarcoma

The combination of doxorubicin and trabectedin significantly improves progression-free survival compared to doxorubicin alone for the first-line treatment of metastatic or unresectable leiomyosarcoma, with an acceptable safety profile despite increased toxicity.

ABOG Certifying Exam Tips

Publications Update # 49

Negotiations for your next job, detection of ovarian cancer recurrences and the role of trabectedin in ovarian cancer (mito-23 trial). Statistics and sample size calculations for board preparation

Publications Update # 48

Stress Management, Mini-Tutorial - Neuroendocrine Tumors of the Cervix, Lymphedema after SLND, Confidence Intervals and osteoporosis

GYOEDU Coaching and Mentoring

Mentoring Sessions with Dr. Shitanshu Uppal: * Over ten years of

GOG 258: Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer

PORTEC 3: Adjuvant chemotherapy vs. radiotherapy in high-risk endometrial cancer

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

Publications Update # 47

Empathy, management of stage IIIC1 endometrial cancer, review article on vulvar cancer and SLND in high risk endometrial cancer